TESTOPROPIONATE - 100mg/ml x 1amp 1ml by Euro Generic Pharm Ltd


TESTOPROPIONATE - 100mg/ml x 1amp 1ml by Euro Generic Pharm Ltd

In stock

Be the first to review this product

Testosterone Propionate

original products
free shipping over 50€


Before use please read this leaflet carefully!

Chemical Name:Testosterone Propionate
Manufacturer:  Euro Generic Pharm Ltd
Pharmacological category:Androgenic hormone
Delivery:1pack 10 amp 100mg

Composition:Every 1 ml contains 100 mg of Testosterone Propionate in Ethyl oleate

Mechanism of medicine action:
The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms:
by activation of the androgen receptor /directly or as DHT/, and by conversion to estradiol and
activation of certain estrogen receptors. Free testosterone is transported into cytoplasm of
target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5-a
di-hydrotestosterone by the cytoplasmic enzyme 5-alpha reductase. DHT binds to the same androgen
receptor even more strongly than testosterone, so that its androgenic potency is about 5 times that
of free testosterone. DHT-receptor complex under goes a structural change that allows it to move
into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA.
The areas of binding are called hormone response elements, and influence transcriptional activity
of certain genes, producing the androgen effects. Androgen receptors occur in many different
vertebrate body system tissues, and both males and females respond similarly to similar levels.
Greatly differing amounts of testosterone prenatally, at puberty, and throughout life account
for a share of biological differences between males and females.

Males: Testosterone Propionate is indicated for replacement therapy in conditions associated with
a deficiency or absence of endrogenous testosterone: Primary hypogonadism testicular failure due
to cryptorchidism, bilateral torsion orchitis, vanishing testis syndrome, or orchidectomy. Prologed
androgen treatment will required to maintain sexual characteristics in these and other males who
develop testosterone deficiency after puberty. Testosterone Propionate may be used to stimulate
puberty in carefully selected males with clearly delayed puberty that is not secondary to a
pathologic disorder; puberty is expected to occur spontaneously at a relatively late date. Brief
treatment with conservative doses may occasionally be justified in these patients if they do not
respond to psychologic support. The potential adverse effect on bone maturation should be discussed
with the patient and parents prior to androgen administration. An x-ray of the hand and wrist to
determine bone age should be obtained every 6 months to assess the effect of treatment on the
epiphyseal centers. Females: Testosterone Propionate may be used secondarily in women with advancing
inoperable metastatic mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy
in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are
adrenalectomy, hypophysectomy, and antiestrogen therapy. This treatment has also been used in
premenopausal women with breast cancer who have benefited from ophorectomy and are considered to
have a hormone responsive tumor. Judgement concerning androgen therapy should be made by an oncologist
with expertisein this field. Testosterone Propionate has been used for the management of postpartum
breast pain and engorgement.


Testosterone Propionate is contradicted in men with carcinomas of the breast or with known or suspected
carcinomas of the prostate and in women who are or may become pregnant. When administered to pregnant women,
androgens cause virilization of the external genitalia of the female fetus. This virilization includes
clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure.
The degree of masculinization is related to the amount of drug given and the age of the fetus and is most
likely to occur in the female fetus when the drugs are given in the first trimester. If the patient becomes
pregnant while taking these drugs, she should be apprised of the potential hazard of the fetus.

Testosterone Propionate, through its metabolic effects, stimulates the nervous, mental, and physical activities
of a patient. Therefore, it should be used with caution in the presence of cardiovascular and renal diseases,
especially in elderly male. Prolonged administration or excessive dosage may cause inhibition of testicular function.
As a result, oligospermia may develop, and there may be a decrease in ejaculatory volume. Women should be observed
for signs of virilization. Discontinuation of drug therapy at the time mild virilism becomes evident is necessary
to prevent irreversible virilization. Such virilization usually follows administration of androgens at high doses.
A decision may be made by the patient and the physician concerning the degree of virilization that will be tolerated
during treatment for breast carcinoma. Anaphylactoid reactions, although rare, may occur, andtreatment should be
readily available. Hypersensitivity reactions, including rash and dermatitis, have been reported.

Drug interactions:
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.

Testosterone Propionate is administered by intramuscular injection. It must not be given intravenously.
Intramuscular injections should be given deep in the gluteal muscle.

Males: the suggested dosage varies, depending on the age, sex, and diagnosis of the individual patient.
Dosage is adjusted according to the patient's response and the appearance of adverse reactions, and
maintenance doses should be the minimum that produce adequate effect. Replacement therapy in
androgen-deficient males should be in the range of 25 to 50 mg every 2 to 3 times a week. Larger doses
can be given by the doctor, depending of the case. For physique or performance enhancing purposes, the
usual dose is in the range of 200-600 mg per week.

Females: In inoperable carcinoma of the breast, temporary palliation may be obtained in some cases by
therapy with androgens. A dosage of 50-100 mg of Testosterone Propionate administered intramuscularly
3 times weekly recommended.

Store in a dark, dry place, at room temperature. Do not refrigerate. Keep out of reach of children.

Manufactured by: Euro Generic Pharm Ltd.

This medicine must be given only by medical prescription!